Weekly Review with SIAS: US stock rally continues

Insights

Stocks

By Beansprout • 13 May 2024

Why trust Beansprout? We’re licensed by the Monetary Authority of Singapore (MAS).

We share more about UOB and OCBC in the latest Weekly Market Review.

13 may 2024 weekly market review
In this article

What happened?

In this week's Weekly Market Review in partnership with Securities Investors Association Singapore (SIAS), we discuss the positive trends in the global equity market and also share more about the following:

Watch the video to learn more about what we are looking out for this week.

Weekly Market Review

0:26 - Macro update

Last week was a positive week for global equity markets. US initial jobless claims came in sharply higher, suggesting the Fed's next move may be to keep interest rates unchanged.

US stocks bounced back, with the S&P 500 returning to above 5,200.

Gains were led by the Dow Jones Industrial Average, up 2.2%, while the NASDAQ rose by 1.1%. The STI, however, was flat at around 3,300.

The Fed is still expected to maintain interest rates in June, with a high probability of no rate change.

3:20 - Singapore market updates

STI top performers 13 may 2024

STI Top performers:

 

STI worst performers 13 may 2024

STI Worst performers:

4:56 - UOB

  • UOB reported a net profit of $1.49 billion, a 6% increase compared to the previous quarter
  • Net interest margin stabilised at 2.02%
  • Fee income grew 5% compared to the previous quarter, driven by wealth management fees
  • Cost-income ratio remained low at 42%
  • Credit quality remained healthy with an NPL ratio of 1.5%
  • UOB maintained its guidance for 2024, expecting low single-digit loan growth and double-digit fee growth

Read our analysis of UOB’s performance here.

9:20 - OCBC

  • Net profit of $1.98 billion, a growth compared to the previous year and quarter
  • Net interest margin slightly down at 2.27%
  • Fee income grew, driven by life and general insurance as well as trading income
  • Cost-income ratio remained subdued at 37.1%
  • Allowances taken in the first quarter may be worth monitoring in the coming quarters

Read our analysis of OCBC’s performance here.

14:24 - Technical Analysis

Straits Times Index 

  • Despite ending almost flat last week, the STI index has risen 3.5% over the past two weeks, driven by good results from the three banks that have reported.
  • Support levels: 20-day moving average, 50-day moving average, and the Bollinger Band basis (3254 points)
  • Resistance levels: Year-to-date high (3325 points), upper bound of the Bollinger Band (3359 points)
  • Indicators: MACD is negative but converging with the signal line, RSI is at 58, indicating healthy momentum

Dow Jones Index

  • Year-to-date high (39,889 points), support levels at 20-day and 50-day moving averages (38,363 and 38,560 points)
  • MACD indicator shows strong momentum, RSI at 65 indicates healthy momentum
  • Likely to retest year-to-date high soon

S&P 500 Index

  • Testing the upper bound of the Bollinger Band, MACD indicator positive, RSI at 62.1 indicates healthy momentum
  • Likely to test year-to-date high soon, may even break out above previous high if momentum remains strong

Nasdaq Composite Index

  • Did not perform as well as other two indices, muted trading sessions last week
  • MACD indicator shows slowdown in momentum, RSI at 58 indicates healthy momentum
  • Likely to test year-to-date high (16,538 points) but may be affected by CPI data coming out this week

What to look out for this week

Get the full list of Singapore stocks, REITs and ETFs with upcoming dividend payments with our dividend calendar.

Sign up for our free newsletter to get market insights delivered to your mailbox every Sunday!

Gain financial insights in minutes
icon

The newsletter that keeps you up-to-date on the financial markets. It’s fun, informative, and free!

Sign up to our newsletter

Read also

Most Popular

Gain financial insights in minutes

Subscribe to our free weekly newsletter for more insights to grow your wealth

chatbubble Comments

0 comments